Associated Papers
Clinical Characteristics and Molecular Profiling of SF3B1-Mutated Myelodysplastic Syndrome (MDS) in a Real-World Practice.
Wang RR et al.
International Journal of Molecular Sciences, 2026
A framework for the molecular identification of CHIP for clinical research.
Harraka P et al.
Hgg Advances, 2026
Association of ASXL1 and RUNX1 Variants with Splenomegaly in Myelodysplastic Syndromes Based on Next-generation Sequencing and Computed Tomography Data: A Retrospective Study.
Huh Y et al.
Annals of Laboratory Medicine, 2026
Clonal Hematopoiesis and Bone Marrow Infiltration in Patients With Follicular Helper T-Cell Lymphoma of Angioimmunoblastic Type.
Harland L et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc, 2024
Genetics and epidemiology of mutational barcode-defined clonal hematopoiesis.
Stacey SN et al.
Nature Genetics, 2023
Concurrent Zrsr2 mutation and Tet2 loss promote myelodysplastic neoplasm in mice.
Garcia-Ruiz C et al.
Leukemia, 2022
Molecular Pathogenesis of Myeloproliferative Neoplasms: From Molecular Landscape to Therapeutic Implications.
Morsia E et al.
International Journal of Molecular Sciences, 2022
Distinct bone marrow immunophenotypic features define the splicing factor 3B subunit 1 (SF3B1)-mutant myelodysplastic syndromes subtype.
Duetz C et al.
British Journal of Haematology, 2021
Diagnosis and prognosis are supported by integrated assessment of next-generation sequencing in chronic myeloid malignancies. A real-life study.
Vantyghem S et al.
Haematologica, 2021
Activating somatic and germline TERT promoter variants in myeloid malignancies.
Nofrini V et al.
Leukemia, 2021
The Molecular Genetics of Myeloproliferative Neoplasms.
Marneth AE et al.
Cold Spring Harbor Perspectives in Medicine, 2020
Proficiency Testing of Standardized Samples Shows High Interlaboratory Agreement for Clinical Next Generation Sequencing-Based Hematologic Malignancy Assays With Survey Material-Specific Differences in Variant Frequencies.
Keegan A et al.
Archives of Pathology & Laboratory Medicine, 2020
A distinct epigenetic program underlies the 1;7 translocation in myelodysplastic syndromes.
Fernandez AGL et al.
Leukemia, 2019
Association of Mutations Contributing to Clonal Hematopoiesis With Prognosis in Chronic Ischemic Heart Failure.
Dorsheimer L et al.
Jama Cardiology, 2019
Gene mutations and clonal architecture in myelodysplastic syndromes and changes upon progression to acute myeloid leukaemia and under treatment.
Stosch JM et al.
British Journal of Haematology, 2018
Disruption of SF3B1 results in deregulated expression and splicing of key genes and pathways in myelodysplastic syndrome hematopoietic stem and progenitor cells.
Dolatshad H et al.
Leukemia, 2015
Recent advances in myelodysplastic syndromes: Molecular pathogenesis and its implications for targeted therapies.
Harada H et al.
Cancer Science, 2015
Age, JAK2(V617F) and SF3B1 mutations are the main predicting factors for survival in refractory anaemia with ring sideroblasts and marked thrombocytosis.
Broséus J et al.
Leukemia, 2013
Recent advances in understanding the molecular pathogenesis of myelodysplastic syndromes.
Kulasekararaj AG et al.
British Journal of Haematology, 2013
Splicing factor mutations in myelodysplasia.
Ogawa S
International Journal of Hematology, 2012
[IDH1/2 gene mutations in myelodysplastic syndromes].
Yoshida K et al.
[rinsho Ketsueki] the Japanese Journal of Clinical Hematology, 2012